IBM and Hangzhou CognitiveCare said 21 hospitals across China will adopt Watson for Oncology trained by Memorial Sloan Kettering, a cognitive computing platform for physicians to help them deliver personalized, evidence-based cancer treatment options. The initial 21-hospital introduction is part of a far-reaching, multi-year partnership through which Hangzhou CognitiveCare will introduce Watson for Oncology to hospitals across China. This is Watson Health’s first partnership in China.
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
